SPDR S&P Biotech ETF
201 hedge funds and large institutions have $2.32B invested in SPDR S&P Biotech ETF in 2016 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
6.86% less ownership
Funds ownership: 119.02% → 112.16% (-6.9%)
39% less call options, than puts
Call options by funds: $539M | Put options by funds: $880M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Holders
201
Holding in Top 10
2
Calls
$539M
Puts
$880M
Top Buyers
1 | +$147M | |
2 | +$86.5M | |
3 | +$26.6M | |
4 |
HI
Honeywell International
Charlotte,
North Carolina
|
+$20.6M |
5 |
![]()
Rafferty Asset Management
New York
|
+$13.2M |
Top Sellers
1 | -$192M | |
2 | -$143M | |
3 | -$41.3M | |
4 |
Bank of America
Charlotte,
North Carolina
|
-$32.5M |
5 |
Millennium Management
New York
|
-$20.6M |